About Selecta Biosciences, Inc
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company’s proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts. Address: 65 Grove Street, Watertown, MA, United States, 02472
Selecta Biosciences, Inc News and around…
Latest news about Selecta Biosciences, Inc (SELB) common stock and company :
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.
-DISSOLVE program on track with 12-month study fully enrolled--DISSOLVE II on track for full enrollment in early 2022--Top-line data from Phase 3 DISSOLVE program expected in H2 2022- WATERTOWN, Mass. and STOCKHOLM, Sweden, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI), today announced the completion of enrollment for DISSOLVE I, the first of two clinical studies of the phase 3 DISSOLVE development program of
Gainers iSpecimen Inc. (NASDAQ: ISPC) climbed 71.7% to settle at $17.51 on Friday. The company recently announced it has been ...
Gainers Allied Healthcare Products, Inc. (NASDAQ: AHPI) shares jumped 68% to $9.04. Shares of mask and protective apparel ...
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 68.43% to $17.18 during Friday's pre-market session. The ...
TheFDA has placed a clinical holdonSelecta Biosciences Inc's(NASDAQ: SELB) Phase 1/2 trial of SEL-302 (which ...
Gainers iSpecimen Inc. (NASDAQ: ISPC) rose 56.9% to $16.00 in pre-market trading. The company recently announced it has been ...
Pre-open movers U.S. stock futures traded lower in early pre-market trade after a new COVID-19 variant was detected in South Africa. ...
Some of the stocks that may grab investor focus today are: Wall Street expects Pinduoduo Inc. (NASDAQ: PDD) to report quarterly ...
Gainers XTL Biopharmaceuticals (NASDAQ:XTLB) shares rose 17.74% to $3.65 during Thursday's after-market session. The market value of ...
The FDA issues a clinical hold on Selecta's (SELB) phase I/II study evaluating SEL-302 for the treatment of patients with methylmalonic acidemia. Shares down in after-hours trading.
-U.S. FDA has issued a clinical hold on Phase 1/2 Clinical Trial of SEL-302 due to CMC related questions-WATERTOWN, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on its Phase 1/2 clinical trial of SEL-302 (wh
Investors in Selecta Biosciences Inc (SELB) saw new options begin trading this week, for the January 2022 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SELB options chain for the new January 2022 contracts and identified one put and one call contract of particular interest.
In this article, we will discuss the 10 best biotech stocks under $5 in 2021. You can skip our detailed analysis of the biotech sector and go directly to the 5 Best Biotech Stocks Under $5. The biotech industry has seen strong growth in terms of funding through venture capitalists, joint ventures, and co-developments in […]
WATERTOWN, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Jefferies London Healthcare Conference, to be held virtually November 18-19, 2021. Details on the conference can b
Benzinga Pro data, Selecta Biosciences (NASDAQ:SELB) reported Q3 sales of $24.43 million. Earnings fell to a loss of $1.97 million, ...
Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of -128.57% and 82.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For ...
-Established four strategic collaborations to advance next generation therapeutics and maximize the potential of ImmTOR platform- -Reported topline data from SEL-399 (empty AAV8 capsid in combination with ImmTOR); Selecta intends continued expansion of ImmTOR platform across gene therapy pipeline- -Continued execution of multiple preclinical programs toward IND- -Further strengthened leadership team with the appointment of Kevin Tan as CFO- -As of September 30, 2021, Selecta had approximately $1
Selecta Biosciences Inc(NASDAQ: SELB)announced top-line resultsfrom the Phase 1 study evaluating the ImmTOR ...
- At day 30, of subjects in the 0.3mg/kg ImmTOR cohort, 100% showed NAb titers of ≤ 1:25, and 67% showed NAb titers of ≤ 1:5 - - With co-administration of AAV8 empty capsids and ImmTOR, Selecta observed dose-dependent response to ImmTOR with a safety profile in line with prior human studies - - Based on these data Selecta intends to rapidly advance its wholly owned gene therapy pipeline, and continue to selectively evaluate gene therapy partnership opportunities utilizing ImmTOR - - Selecta to h
WATERTOWN, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a conference call on Tuesday, November 9, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended September 30, 2021 and provide a business update. Individuals may participate in the l
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares ProShares Ultra Nasdaq Biotechnology ETF (BIB), we found that the implied analyst target price for the ETF based upon its underlying holdings is $130.92 per unit.
Selecta Biosciences, Inc. (SELB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.
Selecta Biosciences Inc (NASDAQ: SELB) and Ginkgo Bioworks Holdings Inc (NYSE: DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases. The partnership will leverage Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies. Selecta has gained rights to develop and commercialize select therapeutic enzymes to treat select auto-immune diseases. Under the terms of the collaboration
Gainers Ocugen (NASDAQ:OCGN) stock increased by 31.15% to $12.25 during Tuesday's pre-market session. The market ...
Selecta Biosciences, Inc. (Nasdaq: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, and Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration to design novel and improved enzymes with transformative therapeutic potential to advance treatments for orphan and rare diseases. This partnership leverages the unique platfor
Selecta Biosciences Inc(NASDAQ: SELB) hasannounced a strategic licensing agreementto advance a next-generation IgG ...
- Selecta obtains from Genovis exclusive worldwide rights to Xork, a differentiated IgG protease - - Selecta combines ImmTOR™ platform with Genovis’ novel IgG protease, Xork, to unlock the full potential of transformative gene therapies and treat certain IgG-mediated autoimmune diseases - - This novel combination has the potential to simultaneously address two of the key hurdles in gene therapy today: pre-existing immunity and the inability to re-dose AAV gene therapies - WATERTOWN, Mass., Oct.
Selecta Biosciences, Inc (SELB) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
